1-4 of 4
Marketa Markova
Close
Sort by
Journal Articles

Clonal Hematopoiesis with Somatic Mutations in "AYA" Generation of Patients with Chronic Myeloid Leukemia

Jitka Koblihova, Vaclava Polivkova, Adela Benesova, Hana Zizkova, Nikola Curik, Monika Pepek, Tomasz Stoklosa, MD PhD, Marketa Markova Stastna, Hana Klamová, Dana Srbova, Katerina Machova
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-140725
Published: 2020
Journal Articles

Significance of Minimal Residual Disease Monitored by Quantitative Assessment of WT1gene in Patients in First Remission of Acute Myeloid Leukemia Before Allogeneic Stem Cell Transplantation

Veronika Válková, Jaroslav Polak, Marketa Markova, Hana Hájková, Antonin Vitek, Mariana Hricinová, Dana Mikulenková, Jaroslav Cermak, MD, PhD, Petr Cetkovsky
Journal: Blood
Blood (2011) 118 (21): 4485.
https://doi.org/10.1182/blood.V118.21.4485.4485
Published: 2011
Journal Articles

Combination Chemotherapy Leading In Advanced MDS Patients to a Rapid Clearence of Bone Marrow Blasts Prior Stem Cell transplantation (SCT) Is Superior to up-Front SCT Even with Intensified Conditioning for Long-Term Survival

Jaroslav Cermak, Antonin Vitek, Marketa Markova, Petr Cetkovsky
Journal: Blood
Blood (2010) 116 (21): 4020.
https://doi.org/10.1182/blood.V116.21.4020.4020
Published: 2010
Journal Articles

Intravascular Tissue Factor (TF) Is Predominantly Platelet-Associated during the Aplastic Phase of Hematopoietic Stem Cell Transplantation (HSCT).

Marketa Markova, MD, Arne Slungaard, MD, Omer Aras, MD, Jessica L. Hysjulien, BS, Janel Long, BS, Arun Shet, MD, Ronald R. Bach, PhD, Nigel S. Key, MD
Journal: Blood
Blood (2004) 104 (11): 1928.
https://doi.org/10.1182/blood.V104.11.1928.1928
Published: 2004